January 1, 2026Journal of Advanced Research1 citationsOpen Access

A novel extracellular vesicle-engineered immunotherapy drug for Her2+ breast cancer

XLXinliang LuFirst Affiliated Hospital Zhejiang University WYWeiyi YuanSouthwest University of Science and Technology XZXianchang ZengSecond Affiliated Hospital of Zhejiang University

Key Points

Key points are not available for this paper at this time.

Abstract

• EVs loaded with a Her2 single-chain variable fragment derived from trastuzumab (EVs/Her2-scFv) showed effective targeting of Her2 + breast cancer. • Compared with trastuzumab, the intrinsic properties of EVs allow EVs/Her2-scFv to penetrate the blood–brain barrier and reduce brain metastases. • EVs/Her2-scFv encapsulated with Rabeprazole (EVs/Her2-scFv/Rabe) showed a remarkable ability to improve TIME and correct aberrant vasculaure associated with Her2 + breast cancer. • EVs/Her2-scFv/Rabe incorporated with CXCL9 (EVs/Her2-scFv/CXCL9/Rabe) further enhanced CD8 + T cell recruitment and infiltration. • The EVs/Her2-scFv/CXCL9/Rabe formulation demonstrated a superior antitumor efficacy compared to liposomal doxorubicin in terms of reduced toxicity. Trastuzumab profoundly improves outcomes of Her2 + breast cancer (BC) patients, but eventual drug resistance is inevitable. Therefore, new treatment options are urgently needed. Here, we modify extracellular vesicles (EVs) with a Her2 single-chain variable fragment of trastuzumab (EVs/Her2-scFv) to target Her2 + BC and found that EVs/Her2-scFv inhibit human Her2 + orthotopic BC comparable to trastuzumab and also uniquely suppress brain metastasies. Moreover, EVs/Her2-scFv loaded with rabeprazole (EVs/Her2-scFv/Rabe) effectively improve tumor immunosuppressive microenvironment and abnormal vasculature of Her2 + BC by reducing tumor EVs. When further anchored with CD8 + T cell chemotactic CXCL9, CXCL9-loaded EVs/Her2-scFv/Rabe (EVs/Her2-scFv/CXCL9/Rabe) facilitate CD8 + T cell recruitment and subsequent activation, thereby exhibiting immunotherapeutic effects on mouse Her2 + BC. In BC patient-derived tumor organoids (PDOs) and peripheral blood mononuclear cell coculture systems, EVs/Her2-scFv/CXCL9/Rabe limit PDO growth by blocking Her2 signaling and activating CD8 + T cells. Besides, EVs/Her2-scFv/CXCL9/Rabe are low-immunogenic with biosafety. Altogether, EVs/Her2-scFv/CXCL9/Rabe hold high potential in Her2 + BC therapy.

Ask AI

Helpful

Bookmark

View Full Paper